RxSight

3800 N Central Ave Ste 460, Phoenix, Arizona, 美国374 名员工

别名:

rxst-us

rxst

rxsight, inc.

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.

概览

试验阶段分布

阶段

试验数

占比

不适用

55.6%

试验状态分布

已完成

77.8%

Enrolling By Invitation

11.1%

终止

11.1%

相关临床试验

该机构主办的试验（9）

Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

Enrolling By Invitation

observational

Nov 2025108 名受试者

RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study

Single Center Exploratory Study To Evaluate The Use Of The RxSight Light Adjustable Lens (LAL) And The Light Delivery Device (LDD) To Improve Visual Outcomes

已完成

interventional

May 202079 名受试者

A Clinical Study to Evaluate The Safety and Effectiveness of The RxSight Light Adjustable Lens (LAL) In Subjects Desiring an Extended Depth of Focus

终止

interventional

Nov 201934 名受试者

A Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)

Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects With Prior Corneal Refractive Surgery

Clinical Study to Evaluate the RxSight Light Adjustable Lens With the Light Delivery Device in Subjects With Preoperative Corneal Astigmatism

Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes

已完成

interventional

Jun 201866 名受试者

第 1 页，共 2 页

药物批准

暂无批准数据

资讯

RxSight Announces Preliminary Q2 2026 Results, Alcon Collaboration, and Next-Generation Light-Adjustable IOL Pipeline

- RxSight reported preliminary Q2 2026 total revenue of approximately $32–$34 million, including $5–$7 million from its newly announced strategic collaboration with Alcon. - The company sold 24,917 Light Adjustable Lens (LAL) units and placed 11 Light Delivery Devices (LDD) in the quarter, while facing what CEO Ron Kurtz described as "meaningful commercial headwinds." - RxSight unveiled a next-generation Light Adjustable Technology platform featuring new LAL, LAL+, and LAL Toric lenses with improved workflow and fewer post-operative treatments. - Full-year 2026 revenue guidance was revised to $140–$160 million, with product sales lowered to $110–$120 million and gross margin raised to 73%–75%.

Jul 6, 2026

返回机构列表